Evaluation of Human Leukocyte Antigen Class I and Class II in End-Stage Renal Disease Occurrence in Indonesian Transplantation Patients

Table 3

Association of two-locus haplotypes with ESRD.

	Haplotypes	ESRD		Control		value	OR	OR 95%CI
		n	%	n	%
HLA-A and HLA-B	A02-B15	26	9.42	14	2.19	0.022	2.273	1.162–4.446
	A24-B35	5	1.81	24	3.59	0.002	0.238	0.089–0.635
	A24-B15	35	12.68	65	10.16	0.016	0.569	0.364–0.890
HLA-A and HLA-C	A02-C08	22	7.97	10	1.56	0.014	2.685	1.249–5.774
	A24-C08	27	9.78	53	8.28	0.020	0.546	0.333–0.896
HLA-A and HLA-DRB1	A24-DRB112	51	18.48	87	13.59	0.015	0.607	0.410–0.897
HLA-A and HLA-DQB1	A24-DQB103	53	19.20	85	13.28	0.042	0.657	0.445–0.969
HLA-B and HLA-C	B35-C04	5	1.81	24	3.75	0.001	0.228	0.086–0.605
HLA-B and HLA-DRB1	B15-DRB112	61	22.10	39	6.09	0.001	2.044	1.317–3.172
	B13-DRB115	9	3.26	1	0.16	0.010	10.75	1.354–85.410
	B35-DRB115	1	0.36	9	1.41	0.036	0.125	0.015–0.998
	B35-DRB112	5	1.81	17	2.66	0.037	0.328	0.119–0.903
HLA-A and HLA-DQB1	B35-DQB103	5	1.81	17	2.66	0.037	0.329	0.120–0.903
	B13-DQB105	8	2.90	1	0.16	0.021	9.522	1.184–76.610

HLA: human leukocyte antigen; ESRD: end-stage renal disease.